Reuters logo
BRIEF-Protalix Biotherapeutics updates on Phase II clinical trial results for Alidornase Alfa
June 7, 2017 / 11:47 AM / 4 months ago

BRIEF-Protalix Biotherapeutics updates on Phase II clinical trial results for Alidornase Alfa

June 7 (Reuters) - Protalix Biotherapeutics Inc:

* Protalix biotherapeutics announces Phase II clinical trial results for Alidornase Alfa in cystic fibrosis presented at the 40th EUROPEAN cystic fibrosis society conference

* “Alidornase Alfa was well tolerated with no serious adverse events reported”

* Protalix Biotherapeutics Inc says clinical data demonstrate over 70% reduction in presence of pseudomonas Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below